98%
921
2 minutes
20
Background And Objective: In oncology, 18-fluorodeoxyglucose (F-FDG) positron emission tomography (PET) / computed tomography (CT) is widely used to identify and analyse metabolically-active tumours. The combination of the high sensitivity and specificity from F-FDG PET and the high resolution from CT makes accurate assessment of disease status and treatment response possible. Since cancer is a systemic disease, whole-body imaging is of high interest. Moreover, whole-body metabolic tumour burden is emerging as a promising new biomarker predicting outcome for innovative immunotherapy in different tumour types. However, this comes with certain challenges such as the large amount of data for manual reading, different appearance of lesions across the body and cumbersome reporting, hampering its use in clinical routine. Automation of the reading can facilitate the process, maximise the information retrieved from the images and support clinicians in making treatment decisions.
Methods: This work proposes a fully automated system for lesion detection and segmentation on whole-body F-FDG PET/CT. The novelty of the method stems from the fact that the same two-step approach used when manually reading the images was adopted, consisting of an intensity-based thresholding on PET followed by a classification that specifies which regions represent normal physiological uptake and which are malignant tissue. The dataset contained 69 patients treated for malignant melanoma. Baseline and follow-up scans together offered 267 images for training and testing.
Results: On an unseen dataset of 53 PET/CT images, a median F1-score of 0.7500 was achieved with, on average, 1.566 false positive lesions per scan. Metabolically-active tumours were segmented with a median dice score of 0.8493 and absolute volume difference of 0.2986 ml.
Conclusions: The proposed fully automated method for the segmentation and detection of metabolically-active lesions on whole-body F-FDG PET/CT achieved competitive results. Moreover, it was compared to a direct segmentation approach which it outperformed for all metrics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2022.106902 | DOI Listing |
Diabetes Obes Metab
September 2025
Turku PET Centre, University of Turku, Turku, Finland.
Aims: Obesity is associated with increased insulin-stimulated brain glucose uptake (BGU) which is opposite to decreased GU observed in peripheral tissues. Increased BGU was shown to be reversed by weight loss and exercise training, but the mechanisms remain unknown. We investigated whether neuroinflammation (TSPO availability) and brain activity drive the obesity-associated increase in BGU and whether this increase is reversed by exercise training.
View Article and Find Full Text PDFCancer Immunol Immunother
September 2025
Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, CHUV/UNIL, 1011, Lausanne, Switzerland.
Background: Immunotherapy is a mainstay in the treatment of patients with advanced melanoma. Yet, resistance mechanisms exist, and tumour-associated macrophages (TAMs), particularly the M2-like phenotype, are associated with poorer outcomes, with CD206 serving as their specific marker. We present the first human SPECT/CT study to visualize CD206 + TAMs in patients undergoing immunotherapy and compare the findings to clinical outcomes (NCT04663126).
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
August 2025
Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515,
Purpose: Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [Ga]Ga-Asp-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp-PEG- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs.
View Article and Find Full Text PDFJ Imaging Inform Med
August 2025
Champalimaud Clinical Centre, Champalimaud Foundation, Av. Brasília, 1400-038, Lisbon, Portugal.
Benefits in patient comfort, efficiency, and sustainability can come from reducing positron emission tomography (PET) scan's acquisition duration. This study assesses the clinical adequacy of restoring fast-acquisition F-fluorodeoxyglucose ([F]FDG) PET to its standard-of-care image quality through deep-learning-based (DL) methods. Fast and standard whole-body [F]FDG PET acquisitions of 117 oncological patients were included in the training and testing of three convolutional neural networks.
View Article and Find Full Text PDF